Mitsubishi Tanabe Pharma issues its news to provide stakeholders with the latest information related to the Company. Information on products or drug candidates may be included, but is intended to provide for the media, etc. It is not intended for promotion, advertising or medical advice.
News Release Formulation of MISSION, VISION 30 and Medium-Term Management Plan 21–25 -Creating hope for all facing illness.-
March 3, 2021
- We have formulated MISSION and VISION 30 that describe our purpose and vision for 2030 as we work to address future social issues
- We have also formulated Medium-Term Management Plan 21–25 that covers the first five years in our efforts to achieve VISION 30
- We will develop precision medicine and around the pill solutions to achieve VISION 30
Mitsubishi Tanabe Pharma Corporation (MTPC, Head Office : Osaka; President & Representative Director : Hiroaki Ueno) announced the formulation of the Company’s MISSION to replace our Philosophy and VISION 30 as our Vision for 2030, having reflected on what MTPC has accomplished to date and re-examined how MTPC should be in society in light of the future outlook for healthcare. In order to lay the foundations for achieving VISION 30, we have also formulated our Medium-Term Management Plan 21–25 covering the period up to fiscal 2025.
For full text, please refer to the link.
- Related information